ProCE Banner Activity


2023 World Conference on Lung Cancer: Expert Perspectives on Key Studies

Text Module

Review expert perspectives on the most clinically relevant data on lung cancers presented at the 2023 IASLC World Conference on Lung Cancer.

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Nurses: 1.50 Nursing contact hours

Physicians: maximum of 1.50 AMA PRA Category 1 Credits

Pharmacists: 1.50 contact hours (0.15 CEUs)

Released: November 17, 2023

Expiration: November 16, 2024



Matthew Gubens

Matthew Gubens, MD, MS, FASCO

Professor of Medicine
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Helena Yu

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Gilead Sciences Inc., and Regeneron Pharmaceuticals, Inc.


Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Regeneron Pharmaceuticals, Inc

Target Audience

This program is intended for physicians, physician associates, nurses, pharmacists, and other healthcare professionals caring for lung cancer patients.

Program Learning Goal

This activity aims to improve learners’ knowledge and competence in optimally applying recent practice-changing findings in treating patients with lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Integrate recently presented data, as appropriate and guided by expert recommendations, to optimize care for patients with lung cancer

  • Distinguish subpopulations of patients with lung cancer most likely to benefit from specific treatment based on prognostic or predictive markers

  • Interpret new data on novel agents and therapeutic strategies for patients with lung cancer to aid optimal integration into practice


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Matthew Gubens, MD, MS, FASCO

Professor of Medicine
Medical Director, Thoracic Medical Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS: consultant/advisor/speaker: AnHeart, AstraZeneca, Atreca, Cardinal Health, Genentech/Roche, Genzyme, Gilead, Guardant, Invitae, iTeos, Merus, Sanofi, Summit, Surface; researcher (paid to institution): Amgen, Celgene, Johnson & Johnson, Merck, Novartis, OncoMed, Trizell.

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Black Diamond, Daiichi Sankyo, Janssen, Taiho, Takeda; researcher: AstraZeneca, Black Diamond, Daiichi Sankyo, Cullinan, ERASCA, Janssen, Novartis, Pfizer.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships, except Kristi K. Orbaugh, MSN, NP, AOCNP, as noted below.

Kristi K. Orbaugh, MSN, NP, AOCNP: consultant/advisor/speaker: AstraZeneca, Bristol-Myers Squibb, CTI, DSI, Gilead, Lilly, MorphoSys, Pfizer.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from November 17, 2023, through November 16, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page
  2. Read the target audience, learning objectives, and faculty disclosures
  3. View and study the content in its entirety
  4. Submit answers to the post-test questions and evaluation questions online

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 


Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.5 contact hours.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.5 contact hours (0.15 CEUs)  of the Accreditation Council for Pharmacy Education.

Universal Activity Number -  JA4008176-0000-23-299-H01-P
Type of Activity: Application

Upon successfully completing the post-test with a score of 65% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Physician Associate Continuing Medical Education
Joint AccreditationClinical Care Options has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credit. Approval is valid until November 16, 2024. PAs should only claim credit commensurate with the extent of their participation.